Expect a Limited Role for Colchicine in Reducing CV Risk

November 2023

You’ll get questions about the role of new Rx colchicine (Lodoco) for patients with chronic coronary disease.

There’s been growing interest in using colchicine to reduce CV risk...due to its anti-inflammatory effect.

Lodoco is the same drug we use for gout...but it’s 0.5 mg instead of 0.6 mg. And it’s the first colchicine approved to reduce CV risk.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Medicare Help Answer Questions About 2024 Medicare Part D Changes
Naloxone Compare Nalmefene and Naloxone for Opioid Overdose Reversal
Diabetes Navigate Risk of Ketoacidosis Due to an SGLT2 Inhibitor
Cardiology Expect a Limited Role for Colchicine in Reducing CV Risk
Hypertension Answer Common Questions About First-Line BP Meds
Infectious Diseases Give Guidance About At-Home Tests for Respiratory Viruses
Cultural Awareness Use Inclusive Language to Reduce Stigma
NatMed Spotlight Be on the Lookout for Interactions With St. John’s Wort